New Zealand markets closed

Intercept Pharmaceuticals, Inc. (ICPT)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
18.37-0.18 (-0.97%)
At close: 04:00PM EST
18.20 -0.17 (-0.93%)
Pre-market: 08:09AM EST
Currency in USD

Valuation measures4

Market cap (intra-day) 667.64M
Enterprise value 509.10M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)1.31
Price/book (mrq)6.20
Enterprise value/revenue 1.34
Enterprise value/EBITDA -4.06

Trading information

Stock price history

Beta (5Y monthly) 1.17
52-week change 318.21%
S&P500 52-week change 3-8.38%
52-week high 321.25
52-week low 310.81
50-day moving average 314.60
200-day moving average 315.37

Share statistics

Avg vol (3-month) 3770.36k
Avg vol (10-day) 3683.69k
Shares outstanding 541.42M
Implied shares outstanding 6N/A
Float 834.02M
% held by insiders 13.15%
% held by institutions 181.37%
Shares short (12 Jan 2023) 43.53M
Short ratio (12 Jan 2023) 43.44
Short % of float (12 Jan 2023) 410.78%
Short % of shares outstanding (12 Jan 2023) 48.51%
Shares short (prior month 14 Dec 2022) 43.53M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)29 Sept 2022


Profit margin 54.33%
Operating margin (ttm)-8.98%

Management effectiveness

Return on assets (ttm)-3.94%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)379.84M
Revenue per share (ttm)12.32
Quarterly revenue growth (yoy)16.40%
Gross profit (ttm)360.37M
EBITDA -33.05M
Net income avi to common (ttm)-157.46M
Diluted EPS (ttm)-2.20
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)490.85M
Total cash per share (mrq)11.85
Total debt (mrq)339.6M
Total debt/equity (mrq)315.39
Current ratio (mrq)2.46
Book value per share (mrq)2.60

Cash flow statement

Operating cash flow (ttm)-17.37M
Levered free cash flow (ttm)-6.31M